Profile data is unavailable for this security.
About the company
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
- Revenue in USD (TTM)42.09m
- Net income in USD-52.01m
- Incorporated2000
- Employees200.00
- LocationCVRx Inc9201 West Broadway Avenue, Suite 650MINNEAPOLIS 55445United StatesUSA
- Phone+1 (763) 416-2850
- Fax+1 (763) 416-2841
- Websitehttps://www.cvrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myomo Inc | 19.55m | -9.34m | 98.26m | 101.00 | -- | 9.01 | -- | 5.03 | -0.2676 | -0.2676 | 0.5775 | 0.3786 | 1.29 | 3.23 | 12.10 | 193,552.80 | -61.73 | -81.78 | -89.94 | -115.27 | 67.39 | 68.50 | -47.77 | -85.76 | 2.40 | -- | 0.00 | -- | 23.70 | 51.09 | 24.00 | -- | 2.82 | -- |
| Fonar Corp | 102.72m | 10.29m | 104.62m | 561.00 | 10.53 | 0.6312 | 5.55 | 1.02 | 1.48 | 1.48 | 14.72 | 24.70 | 0.5023 | 19.99 | 1.41 | 183,098.20 | 7.16 | 8.73 | 7.40 | 9.60 | 45.55 | 48.33 | 14.26 | 16.39 | 9.16 | -- | 0.0051 | -- | 1.08 | 3.89 | -24.71 | -15.05 | 8.48 | -- |
| Akoya Biosciences Inc | 93.57m | -68.01m | 106.18m | 330.00 | -- | 3.24 | -- | 1.13 | -1.47 | -1.47 | 1.99 | 0.6632 | 0.6056 | 2.20 | 7.08 | 283,554.50 | -44.01 | -- | -56.06 | -- | 55.99 | -- | -72.68 | -- | 2.38 | -10.15 | 0.7013 | -- | 29.09 | -- | 10.36 | -- | -- | -- |
| Electromed Inc | 53.50m | 4.36m | 126.55m | 170.00 | 29.58 | 2.97 | 24.44 | 2.37 | 0.4942 | 0.4942 | 6.08 | 4.92 | 1.17 | 3.31 | 2.25 | 314,682.30 | 9.49 | 7.86 | 11.03 | 9.14 | 76.41 | 76.25 | 8.14 | 7.38 | 5.87 | -- | 0.00 | 0.00 | 15.38 | 11.17 | 37.35 | 11.00 | 24.58 | -- |
| TELA Bio Inc | 63.15m | -40.30m | 136.34m | 227.00 | -- | 9.48 | -- | 2.16 | -1.67 | -1.67 | 2.61 | 0.5834 | 0.9668 | 1.37 | 7.60 | 278,180.60 | -61.70 | -52.00 | -79.77 | -60.95 | 68.97 | 65.32 | -63.82 | -107.65 | 3.23 | -8.52 | 0.7387 | -- | 41.13 | 47.85 | -5.35 | -- | -17.12 | -- |
| Clearpoint Neuro Inc | 26.16m | -20.63m | 148.89m | 107.00 | -- | 4.30 | -- | 5.69 | -0.8326 | -0.8326 | 1.05 | 1.26 | 0.5037 | 1.26 | 10.08 | 244,495.30 | -39.71 | -34.75 | -49.90 | -39.67 | 57.10 | 64.75 | -78.84 | -76.91 | 2.61 | -- | 0.2237 | -- | 16.56 | 26.64 | -34.40 | -- | 75.30 | -- |
| CVRx Inc | 42.09m | -52.01m | 150.09m | 200.00 | -- | 2.26 | -- | 3.57 | -2.48 | -2.48 | 2.01 | 3.07 | 0.3678 | 0.6781 | 5.64 | 210,430.00 | -45.45 | -- | -48.95 | -- | 84.45 | -- | -123.58 | -- | 10.87 | -21.11 | 0.3064 | -- | 74.89 | -- | 0.5528 | -- | -- | -- |
| InfuSystem Holdings Inc | 127.41m | 84.00k | 152.05m | 499.00 | 2,568.35 | 2.91 | 12.37 | 1.19 | 0.0028 | 0.0028 | 5.91 | 2.46 | 1.23 | 10.66 | 6.57 | 255,330.70 | 0.0811 | 4.60 | 0.0955 | 5.69 | 50.27 | 56.43 | 0.0659 | 4.07 | 1.51 | 1.56 | 0.3641 | 0.00 | 14.44 | 13.38 | 4,744.44 | -- | 6.01 | -- |
| Stereotaxis Inc | 27.10m | -21.22m | 159.50m | 122.00 | -- | 10.88 | -- | 5.89 | -0.2575 | -0.2575 | 0.3288 | 0.2439 | 0.6012 | 1.45 | 6.14 | 222,155.70 | -44.08 | -25.02 | -63.05 | -34.12 | 55.16 | 67.57 | -73.32 | -41.90 | 1.79 | -- | 0.00 | -- | -4.89 | -1.82 | -12.33 | -- | 6.63 | -- |
| Akso Health Group - ADR | 2.20m | -17.07m | 161.35m | 12.00 | -- | -- | -- | 73.25 | -0.7466 | -0.2461 | 0.0963 | -- | 0.1166 | 1.91 | 0.3202 | 183,560.00 | -89.84 | -17.36 | -224.28 | -23.99 | 7.56 | -- | -770.59 | -256.64 | 1.36 | -24.02 | 0.6531 | -- | 119.69 | -34.25 | -221.68 | -- | -- | -- |
| Accuray Inc | 430.55m | -21.49m | 175.66m | 1.02k | -- | 4.28 | -- | 0.408 | -0.2197 | -0.2197 | 4.42 | 0.4139 | 0.9178 | 1.86 | 5.72 | 420,462.90 | -4.58 | -1.45 | -7.84 | -2.48 | 33.06 | 37.86 | -4.99 | -1.62 | 0.778 | -0.3857 | 0.8086 | -- | 4.12 | 2.03 | -73.56 | -- | 13.92 | -- |
| Outset Medical Inc | 125.08m | -168.77m | 192.92m | 480.00 | -- | 2.07 | -- | 1.54 | -3.38 | -3.38 | 2.50 | 1.80 | 0.3529 | 1.82 | 3.53 | 260,577.10 | -47.61 | -41.40 | -54.98 | -47.29 | 24.61 | 5.71 | -134.93 | -159.05 | 5.32 | -32.13 | 0.6786 | -- | 13.00 | 130.43 | -6.04 | -- | 14.27 | -- |
| Inogen Inc | 321.52m | -96.68m | 195.69m | 834.00 | -- | 1.02 | -- | 0.6086 | -4.15 | -4.15 | 13.81 | 8.15 | 0.917 | 6.03 | 6.83 | 385,519.20 | -27.57 | -8.23 | -34.28 | -9.53 | 40.54 | 44.54 | -30.07 | -10.31 | 2.36 | -- | 0.00 | -- | -16.32 | -2.49 | -22.30 | -- | 26.34 | -- |
| Delcath Systems Inc | 4.61m | -49.79m | 195.89m | 76.00 | -- | 12.27 | -- | 42.52 | -2.65 | -2.65 | 0.2357 | 0.5747 | 0.1382 | 0.4545 | 4.56 | 60,618.42 | -149.30 | -116.57 | -249.28 | -243.21 | 70.54 | 71.02 | -1,080.73 | -1,235.37 | 2.25 | -42.25 | 0.3348 | -- | -24.05 | -9.53 | -30.60 | -- | -5.26 | -- |
| Neuropace Inc | 69.07m | -31.51m | 198.79m | 171.00 | -- | 13.84 | -- | 2.88 | -1.18 | -1.18 | 2.59 | 0.4994 | 0.6735 | 1.62 | 6.63 | 403,935.70 | -30.72 | -- | -34.60 | -- | 73.97 | -- | -45.61 | -- | 5.56 | -4.67 | 0.8019 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to CVRx Inc's reporting currency: US Dollar USD
20.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 710.25k | 3.29% |
| Balyasny Asset Management LPas of 31 Mar 2024 | 618.53k | 2.86% |
| Lord, Abbett & Co. LLCas of 31 Mar 2024 | 588.80k | 2.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 571.23k | 2.65% |
| Emerald Advisers LLCas of 31 Mar 2024 | 487.52k | 2.26% |
| Emerald Mutual Fund Advisers Trustas of 31 Mar 2024 | 385.03k | 1.78% |
| Parkman Healthcare Partners LLCas of 31 Mar 2024 | 332.09k | 1.54% |
| Archon Capital Management LLCas of 31 Mar 2024 | 284.41k | 1.32% |
| Geode Capital Management LLCas of 31 Mar 2024 | 256.13k | 1.19% |
| Silvercrest Asset Management Group LLCas of 31 Mar 2024 | 253.97k | 1.18% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
